Orthocell has received regulatory approval from Singapore’s Health Sciences Authority (HSA) for its market leading dental guided bone regeneration product, Striate+™.
Orthocell CEO and MD, Paul Anderson, hosted a webinar this morning to provide an important update on Orthocell’s clinical and commercial plans. Watch the replay:
Orthocell has submitted a regulatory application to the FDA of Thailand to commence sales of its groundbreaking nerve repair device Remplir™, with clearance expected in Q3 CY2025.
Orthocell has announced it has submitted an application to Health Canada for a Medical Device Licence (MDL) to sell its leading nerve repair product Remplir™ into the US$75 million Canadian nerve repair market.
Orthocell’s plans to broaden its commercial footprint in existing and new markets drove the company’s share price up 13.8% this week, according to a special report in Stockhead.
On the back of outstanding early sales traction for Remplir™ in Australia, New Zealand and Singapore, Orthocell has announced that it is accelerating its global expansion into multiple key jurisdictions.
Orthocell has announced that it has received a $3.18 million R&D Tax Incentive Refund for the 2023/2024 financial year.
Orthocell has been featured in a special report on Stockhead highlighting Orthocell’s consistent growth in sales of our regenerative medicine products, Striate+ and Remplir.
Orthocell has recorded a third consecutive quarter of record revenue, reporting $2.21 million in the December ‘24 Quarter.
Orthocell has been featured in The West Australian in an article by Sean Smith titled “Orthocell cracks a new record high.”